Richard D. Hall, MD
Dr. Richard D. Hall is a medical oncologist at UVA Health and UVA Comprehensive Cancer Center in Charlottesville, Virginia. He specializes in the treatment of all types of thoracic malignancies, including non-small cell lung cancer, thymic malignancies, and malignant pleural mesothelioma. He is board-certified in both Internal Medicine and Medical Oncology.[1]
Professional Memberships and Activities
Dr. Hall is a member of the Hoosier Cancer Research Network Thoracic Clinical Trial Working Group, an independent nonprofit clinical research organization. He was recently selected to join the American Society of Clinical Oncology’s ASCO Education Scholar’s Program.[1]
Research
Dr. Hall is a clinical investigator who has designed, developed, and served as the principal investigator for numerous clinical trials. His research interests include novel therapeutics and immunotherapy for the treatment of lung cancer and other thoracic malignancies.
Dr. Hall’s recent publications include:[2]
- Shantzer, L. B., Dougherty, S. C., Bolte, F., Melson, J. W., Reed, D. R., Lynch, A. C., . . . Hall, R. D. (2022). Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report. CLINICAL LUNG CANCER, 24(2), e60-e64. doi:10.1016/j.cllc.2022.11.006
- Morris, B. B., Smith, J. P., Zhang, Q., Jiang, Z., Hampton, O. A., Churchman, M. L., . . . Mayo, M. W. (2022). Replicative Instability Drives Cancer Progression. BIOMOLECULES, 12(11). doi:10.3390/biom12111570
- Bolte, F. J. J., McTavish, S., Wakefield, N., Shantzer, L., Hubbard, C., Krishnaraj, A., . . . Hall, R. D. D. (2022). Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. FRONTIERS IN ONCOLOGY, 12. doi:10.3389/fonc.2022.986236
